LTRN — Lantern Pharma Cashflow Statement
0.000.00%
Last trade - 00:00- $38.18m
- $14.16m
- 18
- 19
- 33
- 12
Annual cashflow statement for Lantern Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -5.91 | -12.4 | -14.3 | -16 | -20.8 |
| Depreciation | |||||
| Non-Cash Items | 1.19 | 1.16 | 2.09 | 1.06 | 0.723 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.939 | 0.6 | -0.612 | 0.538 | 2.23 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -5.65 | -10.6 | -12.8 | -14.3 | -17.8 |
| Capital Expenditures | -0.016 | -0.015 | -0.028 | -0.019 | -0.013 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | -19.5 | 0.207 | -0.911 | 3.38 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.016 | -19.5 | 0.179 | -0.93 | 3.37 |
| Financing Cash Flow Items | -2.75 | -4.78 | 0 | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 23.7 | 63.4 | -2.18 | -0.5 | 0.067 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 18 | 33.3 | -14.8 | -15.8 | -14.4 |